Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.18.7955

Association of rs1219648 in FGFR2 and rs1042522 in TP53 with Premenopausal Breast Cancer in an Iranian Azeri Population  

Saadatian, Zahra (International Branch of Tabriz University of Medical Sciences (Aras))
Gharesouran, Jalal (Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences)
Ghojazadeh, Morteza (Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences)
Ghohari-Lasaki, Sahar (Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences)
Tarkesh-Esfahani, Najime (Department of Biostatistics, University of Social Welfare and Rehabilitation Sciences)
Ardebili, Seyyed Mojtaba Mohaddes (International Branch of Tabriz University of Medical Sciences (Aras))
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.18, 2014 , pp. 7955-7958 More about this Journal
Abstract
Breast cancer is the most common cancer among women in the world. In Iran, the incidence of breast cancer is on the increase. We here studied the association of rs1219648 in FGFR2 and rs1042522 in TP53 and their interaction in development of early onset sporadic breast cancer in Iranian Azeri population to evaluate epistatic effects on the risk of mammary neoplasia. We genotyped the two polymorphisms in 100 women with early onset breast cancer and 100 healthy women by PCR-RFLP. Allele frequency differences were tested using $chi^2$-test with 95% confident intervals. Our results indicated a statistically significant association (p<0.05) between rs1219648, but not rs1042522, and risk of breast cancer. We also found that the combination of FGFR2 major genotype and TP53 hetero genotype had protective effects against breast cancer, while the hetero allele of FGFR2 in combination with the minor genotype of TP53 was associated with a high risk. This study revealed an important crosstalk between two polymorphisms in FGFR2 and TP53 in development of breast cancer. These candidates risk variants should be further evaluated in studies with a larger sample size.
Keywords
Early onset breast cancer; FGFR2; TP53; Single nucleotide polymorphism;
Citations & Related Records
Times Cited By KSCI : 6  (Citation Analysis)
연도 인용수 순위
1 Cherdyntseva NV, Denisov EV, Litviakov NV, et al (2012). Crosstalk between the FGFR2 and TP53 genes in breast cancer: data from an association study and epistatic interaction analysis. DNA Cell Biol, 31, 306-16.   DOI
2 Al-Qasem A, Toulimat M, Tulbah A, et al (2012). The p53 codon 72 polymorphism is associated with risk and early onset of breast cancer among Saudi women. Oncol Lett, 3, 875-8.
3 Ayoub N, Lucas C, Kaddoumi A (2011). Genomics and pharmacogenomics of breast cancer: current knowledge and trends. Asian Pac J Cancer Prev, 12, 1127-40.
4 Buyru N, Tigli H, Dalay N (2003). P53 codon 72 polymorphism in breast cancer. Oncol Rep, 10, 711-4.
5 Denisov EV, Cherdyntseva NV, Litviakov NV, et al (2012). TP53 gene polymorphisms in cancer risk: the modulating effect of ageing, ethnicity and TP53 somatic abnormalities. In 'Tumor Suppressor Genes', Eds Intech, 79-110.
6 Doosti A, Ghasemi-Dehkordi P, Davoudi N (2011). p53 codon72 polymorphism associated with breast cancer in Iranian patients. African J Pharmacy Pharmacol, 5, 1278-81.   DOI
7 Fu F, Wang C, Huang M, et al (2012). Polymorphisms in second intron of the FGFR2 gene are associated with the risk of early-onset breast cancer in Chinese Han women. Tohoku J Exp Med, 226, 221-9.   DOI
8 Garner I (2000). The Nucleic Acid Protocols Handbook. In Eds Humana Press, 3-7.
9 Hu Z, Li X, Yuan R, et al (2010). Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis. Breast Cancer Res Treat, 120, 705-14.   DOI
10 Han W, Woo JH, Yu JH, et al (2011). Common genetic variants associated with breast cancer in Korean women and differential susceptibility according to intrinsic subtype. Cancer Epidemiol Biomarkers Prev, 20, 793-8.   DOI   ScienceOn
11 He XF, Su J, Zhang Y, et al (2011). Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. Breast Cancer Res Treat, 130, 517-29.   DOI
12 Hosokawa K, Aharoni D, Dantes A, et al (1998). Modulation of Mdm2 expression and p53-induced apoptosis in immortalized human ovarian granulosa cells. Endocrinology, 139, 4688-700.
13 Jia C, Cai Y, Ma Y, et al (2010). Quantitative assessment of the effect of FGFR2 gene polymorphism on the risk of breast cancer. Breast Cancer Res Treat, 124, 521-8.   DOI
14 Katoh M (2008). Cancer genomics and genetics of FGFR2 (Review). Int J Oncol, 33, 233-7.
15 Khadang B, Fattahi MJ, Talei A, et al (2007). Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet, 173, 38-42.   DOI   ScienceOn
16 Liang J, Chen P, Hu Z, et al (2008). Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. Carcinogenesis, 29, 2341-6.   DOI   ScienceOn
17 Khan MH, Rashid H, Mansoor Q, et al (2014). Association of the rs1042522 polymorphism with increased risk of prostate adenocarcinoma in the Pakistani population and its HuGE review. Asian Pac J Cancer Prev, 15, 3973-80.   과학기술학회마을   DOI   ScienceOn
18 Li X, Dumont P, Della Pietra A, et al (2005). The codon 47 polymorphism in p53 is functionally significant. J Biol Chem, 280, 24245-51.   DOI   ScienceOn
19 Marian C, Ochs-Balcom HM, Nie J, et al (2011). FGFR2 intronic SNPs and breast cancer risk: associations with tumor characteristics and interactions with exogenous exposures and other known breast cancer risk factors. Int J Cancer, 129, 702-12.   DOI   ScienceOn
20 Liu CL, Hu XP, Guo WD, et al (2013). Case-control study on the fibroblast growth factor receptor 2 gene polymorphisms associated with breast cancer in Chinese Han women. J Breast Cancer, 16, 366-71.   DOI   ScienceOn
21 Ota S, Zhou ZQ, Link JM, et al (2009). The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects. Hum Mol Genet, 18, 2609-21.   DOI   ScienceOn
22 Papadakis EN, Dokianakis DN, Spandidos DA (2000). p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun, 3, 389-92.   DOI   ScienceOn
23 Pouladi N, Kouhsari SM, Feizi MH, et al (2014). Lack of association of intron 3 16 bp polymorphism of TP53 with breast cancer among Iranian-Azeri patients. Asian Pac J Cancer Prev, 15, 2631-4.   DOI   ScienceOn
24 Rai V (2014). The methylenetetrahydrofolate reductase C677T polymorphism and breast cancer risk in asian populations. Asian Pac J Cancer Prev, 15, 5853-60.   과학기술학회마을   DOI
25 Prentice RL, Huang Y, Hinds DA, et al (2009). Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarkers Prev, 18, 3079-85.   DOI   ScienceOn
26 Rahimzadeh M, Baghestani AR, Gohari MR, et al (2014). Estimation of the cure rate in Iranian breast cancer patients. Asian Pac J Cancer Prev, 15, 4839-42.   과학기술학회마을   DOI   ScienceOn
27 Singh V, Rastogi N, Mathur N, et al (2008). Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol, 18, 48-57.   DOI
28 Raskin L, Pinchev M, Arad C, et al (2008). FGFR2 is a breast cancer susceptibility gene in jewish and arab israeli populations. Cancer Epidemiol Biomarkers Prev, 17, 1060-5.   DOI   ScienceOn
29 Shaulian E, Resnitzky D, Shifman O, et al (1997). Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene, 15, 2717-25.   DOI   ScienceOn
30 Sun C, Olopade OI, Di Rienzo A (2010). rs2981582 is associated with FGFR2 expression in normal breast. Cancer Genet Cytogenet, 197, 193-4.   DOI
31 Suspitsin EN, Buslov KG, Grigoriev MY, et al (2003). Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer, 103, 431-3.   DOI   ScienceOn
32 Tarkkonen KM, Nilsson EM, Kahkonen TE, et al (2012). Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth. PLoS One, 7, 49970.   DOI
33 Zhang Z, Wang M, Wu D, et al (2010b). P53 codon 72 polymorphism contributes to breast cancer risk: a metaanalysis based on 39 case-control studies. Breast Cancer Res Treat, 120, 509-17.   DOI
34 Turner SD, Bush WS (2011). Multivariate analysis of regulatory SNPs: empowering personal genomics by considering cisepistasis and heterogeneity. Pac Symp Biocomput, 276-87.
35 Zhang J, Qiu LX, Wang ZH, et al (2010a). Current evidence on the relationship between three polymorphisms in the FGFR2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat, 124, 419-24.   DOI
36 Zhang YX, Wang XM, Kang S, et al (2013). Common variants in the PALB2 gene confer susceptibility to breast cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 7149-54.   과학기술학회마을   DOI   ScienceOn
37 Zhuo W, Zhang Y, Xiang Z, et al (2009). Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls. J Exp Clin Cancer Res, 28, 115.   DOI   ScienceOn
38 Long J, Zhang B, Signorello LB, et al (2013). Evaluating genome-wide association study-identified breast cancer risk variants in African-American women. PLoS One, 8, 58350.   DOI   ScienceOn
39 Hunter DJ, Kraft P, Jacobs KB, et al (2007). A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet, 39, 870-4.   DOI   ScienceOn